Cryoablation Combined With Tislelizumab Plus Lenvatinib in Patients With Melanoma Liver Metastasis
Status:
Not yet recruiting
Trial end date:
2024-08-16
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the efficacy and safety of cryoablation combined
with Tislelizumab plus lenvatinib in patients with melanoma liver metastasis.